QDEL Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -2.74% compared to QuidelOrtho's net margin of --. QuidelOrtho's return on equity of -47.52% beat Perspective Therapeutics's return on equity of --.

QuidelOrtho has a consensus price target of --, signalling upside risk potential of 14.72%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than QuidelOrtho, analysts believe Perspective Therapeutics is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.107, which suggesting that the stock is 89.318% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

QuidelOrtho quarterly revenues are $727.1M, which are larger than Perspective Therapeutics quarterly revenues of --. QuidelOrtho's net income of -$19.9M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 1.06x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of -2.74% compared to QuidelOrtho's net margin of -0.42%. QuidelOrtho's return on equity of -47.52% beat Repligen's return on equity of -0.41%.

QuidelOrtho has a consensus price target of --, signalling upside risk potential of 14.72%. On the other hand Repligen has an analysts' consensus of $191.46 which suggests that it could grow by 30.29%. Given that Repligen has higher upside potential than QuidelOrtho, analysts believe Repligen is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.107, which suggesting that the stock is 89.318% less volatile than S&P 500. In comparison Repligen has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.502%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

QuidelOrtho quarterly revenues are $727.1M, which are larger than Repligen quarterly revenues of $154.9M. QuidelOrtho's net income of -$19.9M is lower than Repligen's net income of -$654K. Notably, QuidelOrtho's price-to-earnings ratio is -- while Repligen's PE ratio is 628.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 1.06x versus 13.04x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex has a net margin of -2.74% compared to QuidelOrtho's net margin of 14.52%. QuidelOrtho's return on equity of -47.52% beat Teleflex's return on equity of 5.32%.

QuidelOrtho has a consensus price target of --, signalling upside risk potential of 14.72%. On the other hand Teleflex has an analysts' consensus of $238.68 which suggests that it could grow by 34.65%. Given that Teleflex has higher upside potential than QuidelOrtho, analysts believe Teleflex is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.107, which suggesting that the stock is 89.318% less volatile than S&P 500. In comparison Teleflex has a beta of 1.156, suggesting its more volatile than the S&P 500 by 15.641%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 0.77% to investors and pays a quarterly dividend of $0.34 per share. QuidelOrtho pays -- of its earnings as a dividend. Teleflex pays out 17.93% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

QuidelOrtho quarterly revenues are $727.1M, which are smaller than Teleflex quarterly revenues of $764.4M. QuidelOrtho's net income of -$19.9M is lower than Teleflex's net income of $111M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Teleflex's PE ratio is 35.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 1.06x versus 2.77x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -2.74% compared to QuidelOrtho's net margin of -17.98%. QuidelOrtho's return on equity of -47.52% beat Xtant Medical Holdings's return on equity of -35.98%.

QuidelOrtho has a consensus price target of --, signalling upside risk potential of 14.72%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than QuidelOrtho, analysts believe Xtant Medical Holdings is more attractive than QuidelOrtho.

QuidelOrtho has a beta of 0.107, which suggesting that the stock is 89.318% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

QuidelOrtho has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

QuidelOrtho quarterly revenues are $727.1M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. QuidelOrtho's net income of -$19.9M is lower than Xtant Medical Holdings's net income of -$5M. Notably, QuidelOrtho's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho is 1.06x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.